44 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of the commencement of any action, administrative or legal proceeding, or investigation to which the indemnity given in this Clause 9 may apply, CRH
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
investigation;
perceived risks and benefits of the product candidate under study;
Tenet’s ability to recruit clinical trial investigators with the appropriate
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
” means the cell line described in Appendix 2.1
1.3
“Clinical Trial” means any investigation in human subjects intended to discover or verify … warrants that it is not under investigation for violations of such laws, and will inform ValenzaBio in writing immediately if it or any party who
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
audit, claim, dispute, examination, investigation, or other Proceeding in respect of Tax matters.
“Tax Return” means any report, return, election … respect. To the knowledge of Seller, no investigation or review by any Governmental Authority is pending or has been threatened or is reasonably
8-K
EX-99.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
product’s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and
FDA review
DEFM14A
5ceu57q0l63
4 Jun 24
Proxy related to merger
8:00am
PREM14A
4trss52b
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
hdf02 tsc0zb2s4
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
pkusx5g06 wzo
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
7sy7 plajtpjei8
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
x4umoikdgn7
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
dc3gnq
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
pmv2z
14 Nov 22
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
6:10am